Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute€Coronar
Table 3 from Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. | Semantic Scholar
Efficacy outcomes at 30 days in CHAMPION-PHOENIX trial. | Download Table
Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
PPT - CHAMPION PHOENIX PowerPoint Presentation, free download - ID:2257235
Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX | tctmd.com
CHAMPION PHOENIX IPST: Implications of Intraprocedural Stent Thrombosis During PCI from a Prospective, Randomized Trial of a Potent Intravenous ADP Antagonist vs. a Standard Ora... | tctmd.com
CHAMPION PHOENIX trial
Consistent Reduction in MI with Cangrelor Deepak L - ppt download
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial | Journal of the American College of Cardiology
Table 5 from Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use | Semantic Scholar
Figure S1: CHAMPION PHOENIX Study Design | Download Scientific Diagram
PPT - CHAMPION PHOENIX PowerPoint Presentation, free download - ID:2257235
Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial | tctmd.com
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com
Cangrelor Superior to Clopidogrel in CHAMPION PHOENIX Trial | DAIC
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington, - ppt download
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington, - ppt download
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention
PDF) CHAMPION PHOENIX Trial
Pro Position: The Data - Phoenix and Meta-Analysis of the Champion Clinical Trial Program! | tctmd.com
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention | JACC: Cardiovascular Interventions
